Maclagan Laura C, Emdin Abby, Fu Longdi, Guan Jun, de Oliveira Claire, Marras Connie, Bronskill Susan E
Life Stage Research Program (LCM, LF, JG, CO, CM, SEB), ICES; Division of Epidemiology (AE, SEB) and Institute of Health Policy, Management & Evaluation (CO, CM, SEB), Dalla Lana School of Public Health, University of Toronto; Edmond J Safra Program in Parkinson Disease (CM), Toronto Western Hospital; Sunnybrook Research Institute (SEB), Sunnybrook Health Sciences Centre; and Women's College Research Institute (SEB), Women's College Hospital, Toronto, Ontario Canada.
Neurol Clin Pract. 2025 Feb;15(1):e200371. doi: 10.1212/CPJ.0000000000200371. Epub 2024 Oct 8.
Few estimates of the long-term health system costs of Parkinson disease by phase of disease are available. We estimated 10-year and phase-based net health system costs of Parkinson disease before and after case ascertainment.
Using population-based linked administrative databases from Ontario, Canada, we identified 43,149 community-dwelling persons with incident Parkinson disease aged 40 years and older between 2009 and 2018 using a validated algorithm. These individuals were matched 1:1 to controls without Parkinson disease based on demographics and a propensity score. We calculated phase-based, net health system costs from the provincial government perspective during the preascertainment (3 years before index), initial (1 year after index), early continuing (>1-6 years after index), later continuing (>6-10 years after index), and terminal (1 year before death, if applicable) phases (standardized to 2020 $CAD and calculated on an annual basis). By applying survival probabilities to monthly cost estimates, we also determined 10-year net health system costs, stratified by sex and age.
Annual mean net costs of Parkinson disease were lowest in the preascertainment phase ($212 CAD, 95% CI [$20-$404]), intermediate in the initial phase ($4,576 (95% CI [$4,217-$4,935]), and higher in the early continuing phase ($7,078, 95% CI [$6,717-$7,438]). The later continuing phase ($12,500, 95% CI [$12,060-$12,940]) and the terminal phase ($13,933, 95% CI [$13,123-$14,743]) showed the highest costs. The 10-year net cost of Parkinson disease was $82,153 (95% CI [$77,965-$86,341]) and was significantly higher in women ($89,773, 95% CI [$83,306-$96,240]) than in men ($76,469, 95% CI [$70,983-$81,953]) and older individuals ($92,197, 95% CI [$87,087-$97,307]), compared with younger individuals ($62,580, 95% CI [$55,346-$69,814]). Over the 10-year period, hospital, nursing home, and home care were the largest contributors to costs of Parkinson disease.
Health system costs of Parkinson disease are substantial, particularly in the later phases. Interventions to reduce avoidable use of hospital and nursing home services by persons living with Parkinson disease may provide better quality of life and be cost saving from the health system perspective.
关于帕金森病不同阶段长期卫生系统成本的估计很少。我们估计了病例确诊前后帕金森病10年及基于阶段的净卫生系统成本。
利用加拿大安大略省基于人群的关联行政数据库,我们使用经过验证的算法,确定了2009年至2018年间43149名年龄在40岁及以上的社区居住帕金森病新发患者。根据人口统计学和倾向得分,将这些个体与无帕金森病的对照个体进行1:1匹配。我们从省政府的角度计算了确诊前(索引前3年)、初始阶段(索引后1年)、早期持续阶段(索引后>1 - 6年)、后期持续阶段(索引后>6 - 10年)和终末期(如适用,死亡前1年)各阶段基于阶段的净卫生系统成本(标准化为2020年加元并按年度计算)。通过将生存概率应用于每月成本估计,我们还确定了按性别和年龄分层的10年净卫生系统成本。
帕金森病的年均净成本在确诊前阶段最低(212加元,95%置信区间[20 - 404加元]),初始阶段中等(4576加元(95%置信区间[4217 - 4935加元]),早期持续阶段较高(7078加元,95%置信区间[6717 - 7438加元])。后期持续阶段(12500加元,95%置信区间[12060 - 12940加元])和终末期(13933加元,95%置信区间[13123 - 14743加元])成本最高。帕金森病的10年净成本为82153加元(95%置信区间[77965 - 86341加元]),女性(89773加元,95%置信区间[83306 - 96240加元])显著高于男性(76469加元,95%置信区间[70983 - 81953加元]),老年人(92197加元,95%置信区间[87087 - 97307加元])高于年轻人(62580加元,95%置信区间[55346 - 69814加元])。在10年期间,医院、养老院和家庭护理是帕金森病成本的最大贡献者。
帕金森病的卫生系统成本很高,特别是在后期阶段。减少帕金森病患者对医院和养老院服务的可避免使用的干预措施可能会提供更好的生活质量,并从卫生系统角度节省成本。